NEW2026 · Text us +1 272-529-4722
Amlodipine/valsartan is an oral, fixed-dose combination prescription tablet pairing a dihydropyridine calcium channel blocker (CCB) with a non-heterocyclic angiotensin II receptor blocker (ARB). Clinically, this combination tablet is indicated for the treatment of hypertension . It is utilized within two primary management frameworks: Step-Up Combination Therapy: For patients whose blood pressure is not adequately controlled on amlodipine (or an alternative CCB) alone, or on valsartan (or an alt
Reviewed by:
Dr. Steve Malen, PharmD
Dr. Steven Blikstein, PharmD
Strength
How would you like to get this medication?
Choose a strength and quantity to continue.
Amlodipine/valsartan is an oral, fixed-dose combination prescription tablet pairing a dihydropyridine calcium channel blocker (CCB) with a non-heterocyclic angiotensin II receptor blocker (ARB). Clinically, this combination tablet is indicated for the treatment of hypertension . It is utilized within two primary management frameworks: Step-Up Combination Therapy: For patients whose blood pressure is not adequately controlled on amlodipine (or an alternative CCB) alone, or on valsartan (or an alternative ARB) alone. Initial Baseline Therapy: For patients requiring multiple agents to achieve intensive blood pressure targets, typically those with baseline blood pressure more than 20/10 mmHg above their specific clinical goal. By combining two distinct mechanisms of action—inhibiting calcium ion influx into vascular smooth muscle and blocking the renin-angiotensin-aldosterone system (RAAS)—the formulation delivers a synergistic reduction in peripheral vascular resistance. Crucially, the combination also mitigates certain treatment-limiting side effects inherent to CCB monotherapy.
Complete a health screening
A short questionnaire about your health history and current symptoms — takes about 2 minutes.
Provider reviews your answers
A licensed provider reviews your screening answers, typically within 24 hours.
Prescription fulfilled
If approved, your Rx is sent to Invictus Pharmacy and you're notified by text or email. Free nationwide shipping.
Pharmacodynamics and Vasodilatory Synergy
The two active components target peripheral vascular resistance through completely independent, highly complementary physiological pathways:
A common, dose-dependent side effect of amlodipine monotherapy is the development of peripheral ankle edema. This occurs because CCBs cause potent dilation of the afferent arterioles leading into the capillary beds, without dilating the efferent venules. This uncoupling elevates local capillary hydrostatic pressure, forcing fluid into the surrounding interstitial tissue.
When paired with valsartan, the ARB component induces balanced dilation of both the afferent and efferent vascular beds. This restores homeostatic capillary pressure, significantly reducing the incidence and severity of fluid leakage compared to taking high-dose amlodipine alone.
Standard Adult Titration Protocol
Boxed Warning: Fetal Toxicity
Drugs that act directly on the renin-angiotensin system can cause serious injury, developmental abnormalities, and death to the developing fetus.
Severe Hypotension and Volume Depletion
In patients with an activated renin-angiotensin system—such as individuals with severe volume depletion or hyponatremia secondary to high-dose diuretic therapy, strict dietary salt restriction, or persistent vomiting and diarrhea—initiating this tablet can trigger symptomatic, acute hypotension, syncope, or myocardial hypoperfusion. Volume and electrolyte deficits must be fully corrected before administering the first dose.
Impaired Renal Function and Accelerated Azotemia
Inhibiting the RAAS pathway can cause predictable declines in renal perfusion pressure. In patients whose renal function relies heavily on the activity of the renin-angiotensin-aldosterone axis (e.g., individuals with severe congestive heart failure or bilateral renal artery stenosis), treatment with valsartan can precipitate acute oliguria, progressive azotemia, and acute kidney injury (AKI). Serum creatinine, blood urea nitrogen (BUN), and potassium levels must be monitored regularly.
Common Adverse Reactions
The most frequent side effects documented across large-scale clinical registries are typically mild and dose-dependent:
Older adults aged 65 and over exhibit a significantly higher susceptibility to drug-induced renal decline, advanced orthostatic hypotension, and prolonged amlodipine retention due to age-related hepatic clearance drops. Dosing selection should be highly conservative, typically starting at the lowest available combination strength (5 mg / 160 mg), and closely monitored with routine serum chemistry panels.
Administration & Dosage
Amlodipine and valsartan tablets can be taken once daily at any time of day, with or without food — neither component's absorption is significantly affected by meals. Consistency matters more than the specific time chosen: taking the tablet at the same time each day maintains stable blood levels of both amlodipine and valsartan and supports consistent 24-hour blood pressure control. Many patients choose morning dosing as a practical anchor to a daily routine, though evening dosing is equally appropriate. Never stop the combination independently — blood pressure can rise rapidly after discontinuation, and any changes must be made in consultation with your prescribing provider.
Amlodipine begins lowering blood pressure within hours of the first dose, though the full antihypertensive effect of both amlodipine and valsartan at a stable dose typically takes one to two weeks to fully establish. The long half-life of amlodipine means it takes several days of consistent dosing to reach steady-state blood levels, after which blood pressure control becomes more uniform throughout the 24-hour period. Your provider will assess your response at follow-up visits and may adjust the combination strength if the initial response is insufficient. Do not increase your dose independently if you feel the medication is not working quickly enough.
At the standard 5 mg dose, amlodipine typically reduces systolic blood pressure by approximately 8 to 10 mmHg on average, though individual response varies considerably based on baseline pressure, age, and concurrent medications. At 10 mg, reductions of 12 to 15 mmHg systolic are more typical. The valsartan component contributes additional blood pressure lowering through its complementary ARB mechanism — the combined effect of both agents together is meaningfully greater than either component alone. The full sustained reduction at a given dose is established over one to two weeks of consistent daily use rather than immediately after the first dose.
Amlodipine has an exceptionally long plasma half-life of approximately 30 to 50 hours — among the longest of any antihypertensive — meaning it takes about six to seven days of once-daily dosing to reach steady-state blood levels. After stopping, meaningful drug levels persist for several days before the medication fully clears. Valsartan has a much shorter half-life of approximately six hours, but its antihypertensive effect is maintained with once-daily dosing through sustained receptor blockade. The long half-life of the amlodipine component provides smooth, consistent blood pressure control throughout the dosing interval with minimal peak-to-trough variation.
Amlodipine and valsartan combination tablets should not be cut, crushed, or chewed unless your pharmacist confirms that your specific tablet is scored and approved for splitting. Splitting an unscored combination tablet risks uneven distribution of both active ingredients between the two halves, potentially delivering inconsistent doses of amlodipine and valsartan. If dose adjustment is needed, your provider will typically prescribe the appropriate lower-dose tablet rather than directing splitting of a higher-strength tablet. Confirm with your pharmacist before attempting to split any combination antihypertensive tablet.
Take a missed dose as soon as you remember — unless it is almost time for your next dose, in which case skip the missed dose and resume your regular schedule without doubling up. Consistent once-daily dosing is important for sustained blood pressure control, as missed doses allow pressure to rise and undermine the long-term cardiovascular protection this combination is intended to provide. Frequent missed doses can destabilize blood pressure in ways that are not immediately symptomatic but carry cumulative cardiovascular risk. If adherence is consistently difficult, discuss this with your provider or pharmacist.
Uses & Mechanism of Action
Amlodipine and valsartan tablets are used to treat hypertension in adults whose blood pressure is not adequately controlled on either agent alone. The combination pairs a calcium channel blocker with an angiotensin II receptor blocker to lower blood pressure through two distinct and complementary mechanisms, producing greater reductions than typically achievable with monotherapy at equivalent doses. The combination is indicated for patients who require dual antihypertensive therapy and is not appropriate as a first-line treatment for patients who have not yet tried either component individually.
Amlodipine is a long-acting dihydropyridine calcium channel blocker — the vasodilatory component of this combination tablet. It is the same molecule whether described as amlodipine, amlodipine besylate, or the brand name Norvasc — besylate refers only to the salt form used in manufacturing and does not affect pharmacological activity. Amlodipine is not a beta blocker, not a diuretic, and not a water pill — it lowers blood pressure by relaxing blood vessel walls rather than by reducing heart rate or increasing fluid excretion. It belongs to the same calcium channel blocker class as nifedipine and felodipine.
Valsartan is an angiotensin II receptor blocker — the RAAS-targeting component of this combination. It is not a beta blocker, not a statin, and not a diuretic. Valsartan lowers blood pressure by blocking the action of angiotensin II at the AT1 receptor, preventing vasoconstriction and aldosterone-stimulated sodium and water retention. It is the same active ingredient found in the standalone brand Diovan. In the combination tablet, valsartan contributes blood pressure reduction through a mechanism entirely distinct from amlodipine, which is why the two agents work additively when combined.
Amlodipine lowers blood pressure by blocking L-type calcium channels in the smooth muscle cells of peripheral blood vessel walls. Calcium influx through these channels is required for smooth muscle contraction — by blocking this entry, amlodipine prevents vasoconstriction and causes sustained peripheral vasodilation, reducing vascular resistance. This occurs without primarily affecting heart rate, distinguishing it from beta blockers and non-dihydropyridine calcium channel blockers. Amlodipine's gradual onset and long duration of action produce smooth, sustained blood pressure lowering with minimal reflex cardiovascular effects compared to shorter-acting agents in the same class.
Side Effects & Safety
The most commonly reported side effects of amlodipine and valsartan include peripheral edema — swelling of the ankles and feet — attributable to the amlodipine component and reflecting vasodilation rather than fluid retention from kidney dysfunction. Dizziness and lightheadedness, particularly upon standing, are also common when starting treatment or increasing the dose. Headache and flushing are reported with amlodipine. Valsartan-related effects include dizziness and modest creatinine or potassium rises reflecting its ARB hemodynamic effects on the kidney. These effects are generally mild and often improve at a stable dose.
The most clinically serious adverse effects of amlodipine include severe hypotension — particularly in volume-depleted patients or those on multiple antihypertensives — and worsening of angina or myocardial infarction on initiation in patients with obstructive coronary artery disease. Peripheral edema can become severe enough to require dose reduction or discontinuation in some patients. The valsartan component adds its own serious risks — most critically embryo-fetal toxicity, which makes the combination absolutely contraindicated during pregnancy, and hyperkalemia or acute kidney injury in susceptible patients. Any sudden worsening of chest pain, significant leg swelling, or pronounced dizziness after starting this combination warrants prompt medical evaluation.
Amlodipine does not meaningfully lower heart rate in most patients. Unlike non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, which act on cardiac conduction tissue, amlodipine acts selectively on peripheral vascular smooth muscle. Some patients notice a very modest reflex heart rate increase early in treatment as blood pressure falls and baroreceptors compensate, though this is minimal given amlodipine's gradual onset. Valsartan similarly has no significant direct effect on heart rate. If heart rate reduction is a clinical goal alongside blood pressure control, your provider may consider adding a beta blocker to the regimen.
Interactions & Contraindications
Amlodipine and valsartan are absolutely contraindicated during pregnancy — the valsartan ARB component carries an FDA boxed warning for embryo-fetal toxicity, causing severe fetal renal dysplasia, oligohydramnios, and neonatal death when used in the second or third trimester. Women of reproductive potential must use effective contraception and stop the combination immediately if pregnancy occurs. Patients with known hypersensitivity to either component are contraindicated. Amlodipine should be avoided in severe aortic stenosis. Valsartan is contraindicated with aliskiren in diabetic patients. Severe hepatic impairment requires dose assessment for both components.
Amlodipine is metabolized by CYP3A4 — strong inhibitors including ketoconazole, itraconazole, clarithromycin, and ritonavir can significantly increase amlodipine levels, causing excessive blood pressure lowering. CYP3A4 inducers such as rifampin can reduce amlodipine efficacy. Valsartan interactions center on potassium: ACE inhibitors, other ARBs, potassium-sparing diuretics, and potassium supplements increase hyperkalemia risk. NSAIDs reduce the antihypertensive effect of valsartan and can worsen kidney function. Lithium levels may be raised by the valsartan component. Always provide a complete medication list to your prescriber and pharmacist before starting this combination.
Valsartan's ARB mechanism can be nephroprotective in patients with chronic kidney disease — particularly those with diabetic nephropathy and proteinuria — by reducing intraglomerular hypertension. A modest creatinine rise of up to 30% after starting is generally considered acceptable. Significant renal impairment increases hyperkalemia risk with valsartan and warrants closer monitoring. Amlodipine does not require dose adjustment in kidney disease as it is hepatically eliminated. The combination can be used in many CKD patients under appropriate monitoring, though severe renal impairment warrants specialist nephrology involvement in managing the overall antihypertensive regimen.
Generic & Alternatives
The brand name Exforge refers to the amlodipine and valsartan combination tablet, and the generic name is amlodipine and valsartan. Generic amlodipine/valsartan combination tablets are available in the United States in multiple strength combinations — expressed as amlodipine mg/valsartan mg — and are considered bioequivalent to brand-name Exforge by the FDA. Amlodipine besylate is the salt form of amlodipine used in the tablet and is pharmacologically identical to amlodipine — the two terms refer to the same active compound. Your pharmacist can confirm current generic availability.
Yes — amlodipine besylate and amlodipine are the same active drug. Besylate refers to the benzenesulfonate salt form used to stabilize the amlodipine molecule in tablet form and has no pharmacological activity of its own. Once absorbed, amlodipine besylate releases free amlodipine, which produces the blood pressure-lowering effect. All clinical evidence and dosing for amlodipine applies equally to amlodipine besylate — they are interchangeable terms describing the same medication and should not be treated as different drugs when reading prescribing information or clinical studies.
Several alternative combination antihypertensive products pair a calcium channel blocker with an ARB. Amlodipine and olmesartan (Azor), amlodipine and telmisartan (Twynsta), and amlodipine and irbesartan offer the same dual CCB-plus-ARB mechanism with different ARB components. For patients where a different combination class is preferred, ARB-plus-thiazide combinations — such as valsartan-HCTZ — provide an alternative pairing strategy. ACE inhibitor-based combinations are an option for patients without prior ARB-specific indications, though they carry the risk of persistent dry cough. Your provider will recommend the most appropriate combination based on your blood pressure pattern, comorbidities, and tolerability history.
Valsartan lowers blood pressure by selectively blocking the angiotensin II type 1 receptor — through which angiotensin II drives vasoconstriction and aldosterone-stimulated sodium and water retention. By blocking these effects, valsartan causes vasodilation and reduces fluid volume. This mechanism addresses RAAS-driven hypertension from a fundamentally different angle than amlodipine's calcium channel blockade, targeting neurohormonal vasoconstriction rather than vascular smooth muscle directly. The complementary nature of these two mechanisms is what makes the combination particularly effective in patients with multifactorial hypertension.
Amlodipine does not increase urinary frequency — it is not a diuretic, does not contain a diuretic, and has no mechanism that increases urine production. It lowers blood pressure exclusively by relaxing blood vessel walls, with no effect on renal sodium or water handling. Valsartan also has no significant diuretic effect, though it modestly reduces aldosterone levels, affecting sodium handling. If you experience increased urination after starting this combination, other causes — including diabetes, a concurrent medication, or changes in fluid intake — are more likely responsible and should be discussed with your provider.
Valsartan is not associated with weight gain as a pharmacological effect — ARBs do not cause fat accumulation, appetite stimulation, or the metabolic changes that drive weight gain with agents such as corticosteroids or certain antidepressants. Amlodipine can cause peripheral edema — fluid accumulation in the lower limbs — which may appear as a modest increase on the scale without representing true fat gain. If you notice significant weight gain after starting this combination, distinguishing fluid-related weight change from other causes is important. Rapid or substantial weight gain accompanied by increased leg swelling and shortness of breath warrants prompt medical evaluation.
Dry mouth is a recognized but uncommon side effect of amlodipine, appearing in post-marketing reports rather than as a frequently documented adverse event in clinical trials. The mechanism is thought to relate to the effect of calcium channel blockade on salivary gland function in some patients. Staying well hydrated and using saliva substitutes can help manage this symptom if it occurs. Persistent or severe dry mouth should be discussed with your provider, who can assess whether it is related to the medication and whether any adjustment is warranted.
Amlodipine and valsartan must not be used during pregnancy. The valsartan component carries an FDA boxed warning — ARB exposure in the second and third trimesters causes fetal renal dysplasia, oligohydramnios leading to limb contractures and pulmonary hypoplasia, and neonatal renal failure. Even first-trimester ARB exposure should be avoided where possible. Women who become pregnant while taking this combination must contact their provider immediately to transition to a pregnancy-safe antihypertensive such as methyldopa, labetalol, or nifedipine. Effective contraception is required throughout treatment for all women of reproductive potential.
Valsartan is an angiotensin II receptor blocker and is not related to the beta blocker drug class. Beta blockers — such as metoprolol, atenolol, and carvedilol — lower blood pressure by blocking adrenergic receptors on the heart and blood vessels, reducing heart rate and cardiac output. Valsartan works through a completely different mechanism, blocking the AT1 receptor through which angiotensin II drives vasoconstriction and fluid retention. Valsartan is also not a statin, not a diuretic, and not a calcium channel blocker. Understanding the distinction matters clinically — unlike beta blockers, valsartan does not lower heart rate and is not used for rate control in arrhythmias. {"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"When should you take amlodipine and valsartan?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine and valsartan tablets can be taken once daily at any time of day, with or without food — neither component's absorption is significantly affected by meals. Consistency matters more than the specific time chosen: taking the tablet at the same time each day maintains stable blood levels of both amlodipine and valsartan and supports consistent 24-hour blood pressure control. Many patients choose morning dosing as a practical anchor to a daily routine, though evening dosing is equally appropriate. Never stop the combination independently — blood pressure can rise rapidly after discontinuation, and any changes must be made in consultation with your prescribing provider."}},{"@type":"Question","name":"How long does amlodipine take to work?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine begins lowering blood pressure within hours of the first dose, though the full antihypertensive effect of both amlodipine and valsartan at a stable dose typically takes one to two weeks to fully establish. The long half-life of amlodipine means it takes several days of consistent dosing to reach steady-state blood levels, after which blood pressure control becomes more uniform throughout the 24-hour period. Your provider will assess your response at follow-up visits and may adjust the combination strength if the initial response is insufficient. Do not increase your dose independently if you feel the medication is not working quickly enough."}},{"@type":"Question","name":"How much does amlodipine lower blood pressure?","acceptedAnswer":{"@type":"Answer","text":"At the standard 5 mg dose, amlodipine typically reduces systolic blood pressure by approximately 8 to 10 mmHg on average, though individual response varies considerably based on baseline pressure, age, and concurrent medications. At 10 mg, reductions of 12 to 15 mmHg systolic are more typical. The valsartan component contributes additional blood pressure lowering through its complementary ARB mechanism — the combined effect of both agents together is meaningfully greater than either component alone. The full sustained reduction at a given dose is established over one to two weeks of consistent daily use rather than immediately after the first dose."}},{"@type":"Question","name":"How long does amlodipine stay in your system?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine has an exceptionally long plasma half-life of approximately 30 to 50 hours — among the longest of any antihypertensive — meaning it takes about six to seven days of once-daily dosing to reach steady-state blood levels. After stopping, meaningful drug levels persist for several days before the medication fully clears. Valsartan has a much shorter half-life of approximately six hours, but its antihypertensive effect is maintained with once-daily dosing through sustained receptor blockade. The long half-life of the amlodipine component provides smooth, consistent blood pressure control throughout the dosing interval with minimal peak-to-trough variation."}},{"@type":"Question","name":"Can you cut amlodipine and valsartan tablets in half?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine and valsartan combination tablets should not be cut, crushed, or chewed unless your pharmacist confirms that your specific tablet is scored and approved for splitting. Splitting an unscored combination tablet risks uneven distribution of both active ingredients between the two halves, potentially delivering inconsistent doses of amlodipine and valsartan. If dose adjustment is needed, your provider will typically prescribe the appropriate lower-dose tablet rather than directing splitting of a higher-strength tablet. Confirm with your pharmacist before attempting to split any combination antihypertensive tablet."}},{"@type":"Question","name":"What should you do if you miss a dose?","acceptedAnswer":{"@type":"Answer","text":"Take a missed dose as soon as you remember — unless it is almost time for your next dose, in which case skip the missed dose and resume your regular schedule without doubling up. Consistent once-daily dosing is important for sustained blood pressure control, as missed doses allow pressure to rise and undermine the long-term cardiovascular protection this combination is intended to provide. Frequent missed doses can destabilize blood pressure in ways that are not immediately symptomatic but carry cumulative cardiovascular risk. If adherence is consistently difficult, discuss this with your provider or pharmacist."}},{"@type":"Question","name":"What is amlodipine and valsartan used for?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine and valsartan tablets are used to treat hypertension in adults whose blood pressure is not adequately controlled on either agent alone. The combination pairs a calcium channel blocker with an angiotensin II receptor blocker to lower blood pressure through two distinct and complementary mechanisms, producing greater reductions than typically achievable with monotherapy at equivalent doses. The combination is indicated for patients who require dual antihypertensive therapy and is not appropriate as a first-line treatment for patients who have not yet tried either component individually."}},{"@type":"Question","name":"What is amlodipine?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine is a long-acting dihydropyridine calcium channel blocker — the vasodilatory component of this combination tablet. It is the same molecule whether described as amlodipine, amlodipine besylate, or the brand name Norvasc — besylate refers only to the salt form used in manufacturing and does not affect pharmacological activity. Amlodipine is not a beta blocker, not a diuretic, and not a water pill — it lowers blood pressure by relaxing blood vessel walls rather than by reducing heart rate or increasing fluid excretion. It belongs to the same calcium channel blocker class as nifedipine and felodipine."}},{"@type":"Question","name":"What is valsartan?","acceptedAnswer":{"@type":"Answer","text":"Valsartan is an angiotensin II receptor blocker — the RAAS-targeting component of this combination. It is not a beta blocker, not a statin, and not a diuretic. Valsartan lowers blood pressure by blocking the action of angiotensin II at the AT1 receptor, preventing vasoconstriction and aldosterone-stimulated sodium and water retention. It is the same active ingredient found in the standalone brand Diovan. In the combination tablet, valsartan contributes blood pressure reduction through a mechanism entirely distinct from amlodipine, which is why the two agents work additively when combined."}},{"@type":"Question","name":"How amlodipine works","acceptedAnswer":{"@type":"Answer","text":"Amlodipine lowers blood pressure by blocking L-type calcium channels in the smooth muscle cells of peripheral blood vessel walls. Calcium influx through these channels is required for smooth muscle contraction — by blocking this entry, amlodipine prevents vasoconstriction and causes sustained peripheral vasodilation, reducing vascular resistance. This occurs without primarily affecting heart rate, distinguishing it from beta blockers and non-dihydropyridine calcium channel blockers. Amlodipine's gradual onset and long duration of action produce smooth, sustained blood pressure lowering with minimal reflex cardiovascular effects compared to shorter-acting agents in the same class."}},{"@type":"Question","name":"How valsartan works","acceptedAnswer":{"@type":"Answer","text":"Valsartan lowers blood pressure by selectively blocking the angiotensin II type 1 receptor — through which angiotensin II drives vasoconstriction and aldosterone-stimulated sodium and water retention. By blocking these effects, valsartan causes vasodilation and reduces fluid volume. This mechanism addresses RAAS-driven hypertension from a fundamentally different angle than amlodipine's calcium channel blockade, targeting neurohormonal vasoconstriction rather than vascular smooth muscle directly. The complementary nature of these two mechanisms is what makes the combination particularly effective in patients with multifactorial hypertension."}},{"@type":"Question","name":"What are the side effects of amlodipine and valsartan?","acceptedAnswer":{"@type":"Answer","text":"The most commonly reported side effects of amlodipine and valsartan include peripheral edema — swelling of the ankles and feet — attributable to the amlodipine component and reflecting vasodilation rather than fluid retention from kidney dysfunction. Dizziness and lightheadedness, particularly upon standing, are also common when starting treatment or increasing the dose. Headache and flushing are reported with amlodipine. Valsartan-related effects include dizziness and modest creatinine or potassium rises reflecting its ARB hemodynamic effects on the kidney. These effects are generally mild and often improve at a stable dose."}},{"@type":"Question","name":"What are the worst side effects of amlodipine?","acceptedAnswer":{"@type":"Answer","text":"The most clinically serious adverse effects of amlodipine include severe hypotension — particularly in volume-depleted patients or those on multiple antihypertensives — and worsening of angina or myocardial infarction on initiation in patients with obstructive coronary artery disease. Peripheral edema can become severe enough to require dose reduction or discontinuation in some patients. The valsartan component adds its own serious risks — most critically embryo-fetal toxicity, which makes the combination absolutely contraindicated during pregnancy, and hyperkalemia or acute kidney injury in susceptible patients. Any sudden worsening of chest pain, significant leg swelling, or pronounced dizziness after starting this combination warrants prompt medical evaluation."}},{"@type":"Question","name":"Does amlodipine lower heart rate?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine does not meaningfully lower heart rate in most patients. Unlike non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, which act on cardiac conduction tissue, amlodipine acts selectively on peripheral vascular smooth muscle. Some patients notice a very modest reflex heart rate increase early in treatment as blood pressure falls and baroreceptors compensate, though this is minimal given amlodipine's gradual onset. Valsartan similarly has no significant direct effect on heart rate. If heart rate reduction is a clinical goal alongside blood pressure control, your provider may consider adding a beta blocker to the regimen."}},{"@type":"Question","name":"Does amlodipine make you pee more?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine does not increase urinary frequency — it is not a diuretic, does not contain a diuretic, and has no mechanism that increases urine production. It lowers blood pressure exclusively by relaxing blood vessel walls, with no effect on renal sodium or water handling. Valsartan also has no significant diuretic effect, though it modestly reduces aldosterone levels, affecting sodium handling. If you experience increased urination after starting this combination, other causes — including diabetes, a concurrent medication, or changes in fluid intake — are more likely responsible and should be discussed with your provider."}},{"@type":"Question","name":"Does valsartan cause weight gain?","acceptedAnswer":{"@type":"Answer","text":"Valsartan is not associated with weight gain as a pharmacological effect — ARBs do not cause fat accumulation, appetite stimulation, or the metabolic changes that drive weight gain with agents such as corticosteroids or certain antidepressants. Amlodipine can cause peripheral edema — fluid accumulation in the lower limbs — which may appear as a modest increase on the scale without representing true fat gain. If you notice significant weight gain after starting this combination, distinguishing fluid-related weight change from other causes is important. Rapid or substantial weight gain accompanied by increased leg swelling and shortness of breath warrants prompt medical evaluation."}},{"@type":"Question","name":"Does amlodipine cause dry mouth?","acceptedAnswer":{"@type":"Answer","text":"Dry mouth is a recognized but uncommon side effect of amlodipine, appearing in post-marketing reports rather than as a frequently documented adverse event in clinical trials. The mechanism is thought to relate to the effect of calcium channel blockade on salivary gland function in some patients. Staying well hydrated and using saliva substitutes can help manage this symptom if it occurs. Persistent or severe dry mouth should be discussed with your provider, who can assess whether it is related to the medication and whether any adjustment is warranted."}},{"@type":"Question","name":"Who should not take amlodipine and valsartan?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine and valsartan are absolutely contraindicated during pregnancy — the valsartan ARB component carries an FDA boxed warning for embryo-fetal toxicity, causing severe fetal renal dysplasia, oligohydramnios, and neonatal death when used in the second or third trimester. Women of reproductive potential must use effective contraception and stop the combination immediately if pregnancy occurs. Patients with known hypersensitivity to either component are contraindicated. Amlodipine should be avoided in severe aortic stenosis. Valsartan is contraindicated with aliskiren in diabetic patients. Severe hepatic impairment requires dose assessment for both components."}},{"@type":"Question","name":"What drugs interact with amlodipine and valsartan?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine is metabolized by CYP3A4 — strong inhibitors including ketoconazole, itraconazole, clarithromycin, and ritonavir can significantly increase amlodipine levels, causing excessive blood pressure lowering. CYP3A4 inducers such as rifampin can reduce amlodipine efficacy. Valsartan interactions center on potassium: ACE inhibitors, other ARBs, potassium-sparing diuretics, and potassium supplements increase hyperkalemia risk. NSAIDs reduce the antihypertensive effect of valsartan and can worsen kidney function. Lithium levels may be raised by the valsartan component. Always provide a complete medication list to your prescriber and pharmacist before starting this combination."}},{"@type":"Question","name":"Can amlodipine and valsartan be used in kidney disease?","acceptedAnswer":{"@type":"Answer","text":"Valsartan's ARB mechanism can be nephroprotective in patients with chronic kidney disease — particularly those with diabetic nephropathy and proteinuria — by reducing intraglomerular hypertension. A modest creatinine rise of up to 30% after starting is generally considered acceptable. Significant renal impairment increases hyperkalemia risk with valsartan and warrants closer monitoring. Amlodipine does not require dose adjustment in kidney disease as it is hepatically eliminated. The combination can be used in many CKD patients under appropriate monitoring, though severe renal impairment warrants specialist nephrology involvement in managing the overall antihypertensive regimen."}},{"@type":"Question","name":"Can amlodipine and valsartan be used during pregnancy?","acceptedAnswer":{"@type":"Answer","text":"Amlodipine and valsartan must not be used during pregnancy. The valsartan component carries an FDA boxed warning — ARB exposure in the second and third trimesters causes fetal renal dysplasia, oligohydramnios leading to limb contractures and pulmonary hypoplasia, and neonatal renal failure. Even first-trimester ARB exposure should be avoided where possible. Women who become pregnant while taking this combination must contact their provider immediately to transition to a pregnancy-safe antihypertensive such as methyldopa, labetalol, or nifedipine. Effective contraception is required throughout treatment for all women of reproductive potential."}},{"@type":"Question","name":"What is the generic name for Exforge?","acceptedAnswer":{"@type":"Answer","text":"The brand name Exforge refers to the amlodipine and valsartan combination tablet, and the generic name is amlodipine and valsartan. Generic amlodipine/valsartan combination tablets are available in the United States in multiple strength combinations — expressed as amlodipine mg/valsartan mg — and are considered bioequivalent to brand-name Exforge by the FDA. Amlodipine besylate is the salt form of amlodipine used in the tablet and is pharmacologically identical to amlodipine — the two terms refer to the same active compound. Your pharmacist can confirm current generic availability."}},{"@type":"Question","name":"Is amlodipine besylate the same as amlodipine?","acceptedAnswer":{"@type":"Answer","text":"Yes — amlodipine besylate and amlodipine are the same active drug. Besylate refers to the benzenesulfonate salt form used to stabilize the amlodipine molecule in tablet form and has no pharmacological activity of its own. Once absorbed, amlodipine besylate releases free amlodipine, which produces the blood pressure-lowering effect. All clinical evidence and dosing for amlodipine applies equally to amlodipine besylate — they are interchangeable terms describing the same medication and should not be treated as different drugs when reading prescribing information or clinical studies."}},{"@type":"Question","name":"Are there alternatives to amlodipine and valsartan?","acceptedAnswer":{"@type":"Answer","text":"Several alternative combination antihypertensive products pair a calcium channel blocker with an ARB. Amlodipine and olmesartan (Azor), amlodipine and telmisartan (Twynsta), and amlodipine and irbesartan offer the same dual CCB-plus-ARB mechanism with different ARB components. For patients where a different combination class is preferred, ARB-plus-thiazide combinations — such as valsartan-HCTZ — provide an alternative pairing strategy. ACE inhibitor-based combinations are an option for patients without prior ARB-specific indications, though they carry the risk of persistent dry cough. Your provider will recommend the most appropriate combination based on your blood pressure pattern, comorbidities, and tolerability history."}},{"@type":"Question","name":"Is valsartan a beta blocker?","acceptedAnswer":{"@type":"Answer","text":"Valsartan is an angiotensin II receptor blocker and is not related to the beta blocker drug class. Beta blockers — such as metoprolol, atenolol, and carvedilol — lower blood pressure by blocking adrenergic receptors on the heart and blood vessels, reducing heart rate and cardiac output. Valsartan works through a completely different mechanism, blocking the AT1 receptor through which angiotensin II drives vasoconstriction and fluid retention. Valsartan is also not a statin, not a diuretic, and not a calcium channel blocker. Understanding the distinction matters clinically — unlike beta blockers, valsartan does not lower heart rate and is not used for rate control in arrhythmias."}}]}